Literature summary for 3.4.21.77 extracted from

Pinkawa, M.; Piroth, M.D.; Holy, R.; Fischedick, K.; Schaar, S.; Borchers, H.; Heidenreich, A.; Eble, M.J.
Prostate-specific antigen kinetics following external-beam radiotherapy and temporary (Ir-192) or permanent (I-125) brachytherapy for prostate cancer (2010), Radiother. Oncol., 96, 25-29.

Search for more literature for 3.4.21.77

Application

Application	Comment	Organism
medicine	PSA kinetics differ significantly following different radiotherapy methods. A higher radiobiological efficiency of brachytherapy in comparison to external-beam radiotherapy (with a total dose of 70.2 Gy) in respect of normal prostate tissue (lower PSA nadir for patients without biochemical failure) and malignant prostate cells (lower PSA failure rate). PSA bounces occur predominantly in the first three years after treatment, particularly after low-dose-rate-brachytherapy	Homo sapiens

Organism

Organism	UniProt	Comment	Textmining
Homo sapiens	-	-	-

Source Tissue

Source Tissue	Comment	Organism	Textmining
additional information	malignant and normal prostate cells	Homo sapiens	-

Synonyms

Synonyms	Comment	Organism
prostate-specific antigen	-	Homo sapiens
PSA	-	Homo sapiens

General Information

General Information	Comment	Organism
physiological function	PSA bounces are found predominantly in the low-dose-rate-brachytherapy group (42% vs. 23%/20% after high-dose-rate-brachytherapy/external-beam radiotherapy). More patients reach a PSA lower than 0.5 ng/ml after brachytherapy in comparison to external-beam radiotherapy already after 12 months. The percentage increases in the following years, the majority of patients present with a PSA more than 0.2 ng/ml 36 months after brachytherapy	Homo sapiens

Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.

Release 2023.1 (January 2023)